Hims & Hers Health is trading at €22.42, down 5.80%, with no specific reason for the November 3 move identified.
- Coverage around November 2 focused on the lead-plaintiff deadline in a securities class action connected to allegations in the FTC’s July complaint; sources do not establish that the deadline caused the price change.
- Market context shows no significant same-direction index move to explain the decline, and the available evidence does not identify a specific reason.